155 related articles for article (PubMed ID: 38352847)
21. Novel PCSK9 Inhibitors for Treating Cardiovascular Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 Apr; 15(4):443-444. PubMed ID: 38628783
[TBL] [Abstract][Full Text] [Related]
22. Novel HSD17B13 Inhibitors for Treating Liver Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 Jun; 15(6):771-772. PubMed ID: 38894932
[TBL] [Abstract][Full Text] [Related]
23. Novel Heterocyclic PAD4 Inhibitors for Treating Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 Mar; 15(3):340-341. PubMed ID: 38505857
[TBL] [Abstract][Full Text] [Related]
24. Novel Heterocyclic PAD4 Inhibitors for Treating Multiple Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 Feb; 15(2):179-180. PubMed ID: 38352837
[TBL] [Abstract][Full Text] [Related]
25. Novel Compounds as TEAD Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2023 Sep; 14(9):1152-1153. PubMed ID: 37736181
[TBL] [Abstract][Full Text] [Related]
26. Novel Pyrazolopyrazine Compounds as SHP2 Inhibitors for Treating Glioblastoma.
Sabnis RW
ACS Med Chem Lett; 2023 Oct; 14(10):1336-1337. PubMed ID: 37849559
[TBL] [Abstract][Full Text] [Related]
27. Novel Indazole Compounds as TEAD Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2023 Oct; 14(10):1334-1335. PubMed ID: 37849539
[TBL] [Abstract][Full Text] [Related]
28. Novel Pyrazoloquinoline Compounds as KRAS Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2023 Aug; 14(8):1045-1046. PubMed ID: 37583830
[TBL] [Abstract][Full Text] [Related]
29. Novel Tricyclic Compounds as KRAS Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2023 May; 14(5):555-556. PubMed ID: 37197476
[TBL] [Abstract][Full Text] [Related]
30. Novel Quinoline Compounds as KRAS Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2023 Jun; 14(6):707-708. PubMed ID: 37312857
[TBL] [Abstract][Full Text] [Related]
31. Novel Heteroaryl Compounds as CD73 Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2024 Jun; 15(6):775-776. PubMed ID: 38894910
[TBL] [Abstract][Full Text] [Related]
32. Novel 2,7-Naphthyridine Compounds as MASTL Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2024 Jun; 15(6):748-749. PubMed ID: 38894901
[TBL] [Abstract][Full Text] [Related]
33. Novel Pyrrole Derivatives as Apolipoprotein L-1 Inhibitors for Treating Kidney Diseases and Sepsis.
Sabnis RW
ACS Med Chem Lett; 2023 Dec; 14(12):1625-1626. PubMed ID: 38116414
[TBL] [Abstract][Full Text] [Related]
34. Discovery of potential RIPK1 inhibitors by machine learning and molecular dynamics simulations.
Liu JX; Na RS; Yang LJ; Huang XR; Zhao X
Phys Chem Chem Phys; 2023 Nov; 25(45):31418-31430. PubMed ID: 37962373
[TBL] [Abstract][Full Text] [Related]
35. Imidazopyridine Compounds as ERK5 Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2024 Jun; 15(6):777-778. PubMed ID: 38894904
[TBL] [Abstract][Full Text] [Related]
36. Novel Furopyridine and Furopyrimidine Compounds as PI4K Inhibitors for Treating Malaria and Viral Infection.
Sabnis RW
ACS Med Chem Lett; 2024 Jun; 15(6):779-780. PubMed ID: 38894915
[TBL] [Abstract][Full Text] [Related]
37. Novel Phosphorylpurinone Compounds for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2024 Apr; 15(4):441-442. PubMed ID: 38628787
[TBL] [Abstract][Full Text] [Related]
38. Targeting RIPK1 for the treatment of human diseases.
Degterev A; Ofengeim D; Yuan J
Proc Natl Acad Sci U S A; 2019 May; 116(20):9714-9722. PubMed ID: 31048504
[TBL] [Abstract][Full Text] [Related]
39. Novel Peptidylarginine Deiminase Type 4 (PAD4) Inhibitors.
Sabnis RW
ACS Med Chem Lett; 2022 Oct; 13(10):1537-1538. PubMed ID: 36267127
[TBL] [Abstract][Full Text] [Related]
40. Novel PARP1 Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2024 Feb; 15(2):161-162. PubMed ID: 38352834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
